ArticleJournal of hepatocellular carcinoma2025
Combined TACE and Microwave Ablation for Recurrent Spiegel-Lobe HCC: A Four-Case Series.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Spiegel lobe, a distinct subdivision of the hepatic caudate lobe, is characterized by its unique anatomical position, with close proximity to major hilar vasculature and extrahepatic structures. Therapeutic intervention for Spiegel lobe lesions remains technically challenging, with no established treatment protocol currently available. Case Presentation: This study reports four cases of recurrent hepatocellular carcinoma (HCC) in the Spiegel lobe treated with conventional transarterial chemoembolization (c-TACE) followed by microwave ablation (MWA) via a transhepatic left lobe approach. Postprocedural imaging assessment confirmed complete response (CR) in all patients according to mRECIST criteria. During a mean follow-up period of 33.75 months (range: 31-37), three patients maintained disease-free status, whereas one patient developed intrahepatic recurrence at 19.2 months. This patient achieved CR after repeat TACE-MWA combined with adjuvant lenvatinib and tislelizumab therapy. The mean overall survival (OS) was 33.75 months (95% CI: 31.2-36.3). Conclusion: The combination of transcatheter arterial chemoembolization (TACE) and microwave ablation (MWA) for treating recurrent hepatocellular carcinoma (HCC) in the Spiegel lobe was proven feasible in this series of studies, and demonstrated favorable efficacy and safety profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.